404 Not Found
nginx/1.6.1Financial World Fund reported on October 28 that the E Fund CSI Wande Biotechnology Index (LOF) A Fund fell 1.13% on October 27, with a current price of 0.972 yuan and a transaction of 351,200 yuan. The current off-market net value of this fund is 0.9489 yuan, down 2.20% from the previous trading day, and the on-market price premium rate is 1.28%.
This fund is a listed tradable stock fund and index fund. Data from the Financial World Fund shows that the net value of this fund fell by 6.19% in the past January, the net value of this fund fell by 7.51% in the past three months, the net value of this fund fell by 14.41% in the past June, and the net value of this fund fell by 1.26% in the past year. Since its establishment, the cumulative net value of this fund has been 1.3492 yuan.
This fund has distributed dividends 0 times since its establishment, with a cumulative dividend amount of RMB 100 million. The fund is currently open for subscription. The fund manager of
is Zhang Zhan, who has managed the fund on December 3, 2020, and has earned 3.25% during his tenure. The latest fund periodic report of
shows that the fund has a heavy holding in WuXi AppTec (holding ratio 10.28%), Zhifei Biotech (holding ratio 9.05%), Tiger Pharmaceutical (holding ratio 8.64%), Watson Biotech (holding ratio 7.78%), Changchun Hi-Tech (holding ratio 7.37%), Kanglong Chemical (holding ratio 5.39%), Kangtai Biotech (holding ratio 4.29%), Hualan Biotech (holding ratio 2.89%), Jinyu Medicine (holding ratio 2.69%), and Medisi (holding ratio 2.19%).
Fund investment strategy and operation analysis during the reporting period
Since the third quarter of 2021, with the continuous increase in the proportion of vaccination, the new crown epidemic has stabilized worldwide, and all major economies have shown a good economic recovery momentum. Signals such as employment and inflation in developed economies such as the United States have enhanced the market's expectations for the reduction of quantitative easing and the arrival of a interest rate hike cycle, and have also brought certain fluctuations to the global market. Under the influence of mature epidemic prevention and control mechanisms, although the domestic epidemic has sporadic regional outbreaks, they have been effectively controlled in a short period of time and have not spread on a large scale. The domestic economy is operating smoothly, but due to factors such as the epidemic and double reduction, the economic growth rate has slowed down. The second quarter and semi-annual reports of listed companies show that the overall performance of enterprises in the biotechnology field has stable growth and performance in line with expectations. Against the backdrop of the accelerated aging process in my country and the gradual improvement of residents' health awareness, the health care industry has huge room for development. In recent years, the number of biotechnology companies in my country has continued to increase, R&D investment has grown rapidly, patent technology has accumulated and precipitated, independent innovation capabilities have been greatly improved, and corporate profitability and stability have also been enhanced, with long-term investment and allocation value.
During the reporting period, this fund constructs the fund stock portfolio according to the composition of the constituent stocks of the target index and its weights, and makes corresponding adjustments based on changes in the constituent stocks of the target index and their weights. On the basis of ensuring the normal operation of the fund, the fund's tracking error and daily average deviation indicators are controlled within the scope agreed in the contract.
Fund performance during the reporting period
